• 12th International Conference on HHV-6 & 7 Announced

    The 12th International Conference on HHV-6 & 7 will convene in Japan at the Himeji Culture and Convention Center in March 2025.

  • Short-course foscarnet at an early stage may suppress HHV-6 reactivation following allogenic HCT

    Observational study suggests that an early one-week treatment at the first sign of viral reactivation may achieve clinical benefits and avoid antiviral toxicity.

  • Herpesvirus Reactivation Common in Severe COVID-19

    HHV-6 was the most common herpesvirus found when tested in nasal swabs, but EBV was the most common in plasma.

  • High levels of HHV-6A DNA found in blood of 52% of kidney transplant patients

    HHV-6A was the most common virus identified, but was not linked to worse outcomes compared to other viral infections.

Newsletter | About Us | Contact Us | Donate | Repository

HHV-6 Foundation | HHV-6 Disease Information for Patients, Clinicians, and Researchers | Apply for a Grant Navigation
  • Home
  • About
    • Scientific Advisory Board
    • Staff
    • Contact Us
    • Donate
  • Patients
    • What Is HHV-6?
    • HHV-6A/B Testing
  • Research
    • Grants
    • Repository
      • Cart
      • Checkout
    • HHV-6A/B Testing
    • List of Genes & Proteins
    • Lab Protocols
    • Pictorial Atlas of HHV-6
    • HHV-6 Antivirals
    • Researcher FAQ
    • Newsletter
  • Home
  • About
    • Scientific Advisory Board
    • Staff
    • Contact Us
    • Donate
  • Patients
    • What Is HHV-6?
    • HHV-6A/B Testing
  • Research
    • Grants
    • Repository
      • Cart
      • Checkout
    • HHV-6A/B Testing
    • List of Genes & Proteins
    • Lab Protocols
    • Pictorial Atlas of HHV-6
    • HHV-6 Antivirals
    • Researcher FAQ
    • Newsletter

Latest Scientific News Articles

View Post

Using CRISPR to excise integrated HHV-6A from latently infected cells and iciHHV6 patient cell lines, in vitro

Advance may aid the study of integration and excision and might ultimately have clinical application.

View Post

The relationship of telomere length to HHV-6 integration

Telomere length does not appear to influence the efficiency of viral integration, and viral integration may not affect telomere length.

View Post

Uncontrolled evidence suggests immunosuppression may be safe and effective in lymphocytic myocarditis patients with biopsies positive for HHV-6 by qPCR

Steroids reduced cardiac inflammation in 70% and improved ejection fraction in 80% without an increase in viral load.

View Post

Differences in the cytopathic effect of HHV-6A and HHV-6B infection of neurons and glia

In vitro studies confirm that the two viruses infect different cell types, and generate different cytopathic effects, cytokine and growth factor responses.

View Post

Murine roseolovirus (MRV) infection experiments are only partially supportive of role of HHV-6A/B in Alzheimer’s disease

While MRV administered peripherally led to brain infection and neuroinflammation, it did not increase Aß deposition

View Post

HHV-6A promotes inflammation in astrocytoma cells by dysregulating autophagy

Infection increases ROS, induces ER stress and activates STAT3, NF-κB and mTOR pathways.

View Post

EBV and HHV-6 plasma viremia is infrequent at Day 7 during acute COVID-19

Other studies have suggested that reactivation of these viruses could theoretically contribute to a hyperinflammatory state or autoimmune disorders in acute COVID-19, but this study does not provide evidence of that.

View Post

Does inherited chromosomal integration of HHV-6 at 9q increase the risk of malignancy?

A large study of iciHHV-6 integration sites found integration at 9q more common in hematologic malignancies—but the study lacked power to draw firm conclusions.

View Post

Development of highly sensitive technique for detecting viral DNA sequences in cell-free plasma

Isolating DNA fragments less than 120 base pairs enriches for viral vs. cellular DNA.

View Post

G-1082A polymorphism of IL-10 may protect against HHV-6/EBV adenoid hypertrophy

The presence of HHV-6 and EBV DNA in nasal secretions correlates with the degree of adenoid hypertrophy in children.

View Post

HHV-6A U14 protein and NFκB activate each other

The late protein U14 of HHV-6A can induce the pro-inflammatory transcription factor NFκB, and NFκB, in turn, can encourage the replication of HHV-6A.

View Post

Different isoforms of CD46 affect infectivity and replication of HHV-6A and HHV-6B

While CD134 remains the more important receptor for HHV-6B, HHV-6B can use the CD46 receptor when a T cell has the C1 isoform of CD46.

View Post

HHV-6B may enter cells that don’t express CD134 via the nectin-2 receptor

If confirmed, finding could explain ability of HHV-6B to infect salivary, liver and neural cells.

View Post

HHV-6A and HCMV induce pro-fibrotic miRNA expression pattern in infected host cells

Pattern consistent with clinical studies suggesting these viruses may be one trigger of systemic sclerosis.

View Post

HHV-6 miRNA inhibits host miRNA to trigger reactivation from latency

A viral miRNA disrupts mitochondrial architecture, suppresses type I interferon production, is necessary for productive infection and for virus reactivation, all by inhibiting multiple members of the host miR-30 family—creating a therapeutic target to suppress reactivation.

  • Page 1 of 9
  • 1
  • 2
  • 3
  • ...
  • 9
  • →

Clinical News

  • Alzheimer’s Disease
  • Animal Models
  • Autoimmune Disease
  • Cancer
  • iciHHV-6
  • CNS Disease
  • COVID-19 / HHV-6 Reactivation
  • Drug Hypersensitivity
  • Encephalitis & Encephalopathy
  • Endocrine Conditions
  • Epilepsy and Seizures
  • Gastrointestinal
  • Genes
  • Heart Disease
  • Hematological Disorders
  • HIV/AIDS Progression
  • Immunity & Immunotherapy
  • Infertility & Miscarriage
  • Kidney Disease
  • Liver Disease
  • Lung Disease
  • Lymphadenopathy & Fever
  • ME/CFS
  • Multiple Sclerosis
  • Rash & Roseola
  • Transplant Complications
  • Treatments – Adoptive T cell
  • Treatments – Alternative
  • Treatments – Antiviral
  • Treatments – Immune Stimulant

About HHV-6

  • What Is HHV-6?
  • What is Inherited Chromosomally Integrated HHV-6
  • HHV-6 Repository of Reagents
  • HHV-6A/B Testing
  • HHV-6 Treatment

SUBSCRIBE TO OUR NEWSLETTER

ABOUT THE HHV-6 FOUNDATION

The HHV-6 Foundation in a non-profit entity founded to encourage scientific exchange between investigators and to provide pilot grants for promising scientific and clinical research on the under- appreciated viruses HHV-6A and HHV-6B.

The Foundation sponsors international conferences and supports scientists and clinicians seeking to clarify the role of the two HHV-6 viruses in disease. Since HHV-6A and HHV-6B can smolder in the brain and other organs without circulating in the peripheral blood or plasma, identifying chronic infection is a challenge.

Read More

HHV-6 Foundation | 1482 East Valley Road, Suite 619 | Santa Barbara, CA, 93108 | Toll Free: (888) 530-6726


Copyright ©2004-2022 HHV-6 FOUNDATION


WEB DESIGN AND DEVELOPMENT BY INSTYLE TECHNOLOGIES
  • Home
  • About
  • Conditions
  • Clinicians
  • Testing
  • Research
  • Repository
  • Patients
  • Treatment
  • News & Blog
  • Donate
  • Contact Us
  • Cart
  • Checkout
  • Privacy Policy
  • Terms of Use